Biotech Values

[ghmm]

i am long spectrum primarily for Satraplatin (though I like getting Eoquin and Ozarelix too) but if I were to buy in to the ASCO leak theory the fact the GPC has been down consistently for a few days now would make me wonder. Of course if could be just people getting nervous about having the panel meeting. GPC has long stated they were preparing for that possibility so I don't think they were shocked by it. I thought the results being excellent and platinum's not being new to Oncology there wouldn't be a need. I'd like to think it is as palindromy suggests
1. ODAC wants to contrast positive outcomes for well-designed statistically robust trials to limit public criticism.. Don't know enough about what would necessitate an ODAC panel but the fact that Satraplatin is the first Oral platinum drug could be a factor too.